主要研究方向：
主要從事血液相關(guān)蛋白與疾病及其療效機制、血漿蛋白結(jié)構(gòu)與功能相關(guān)性研究；血液成分制品安全性、有效性的評價體系建設(shè)及檢測關(guān)鍵技術(shù)與標(biāo)準(zhǔn)化研究；血液相關(guān)蛋白質(zhì)產(chǎn)品及血栓與止血診斷試劑研究開發(fā)等。
Research Platform for Blood Plasma Proteins was re-organized from Blood Plasma Proteins Laboratory and Blood Biochemistry and Molecular Biology Research Center of Institute of Blood Transfusion, CAMS/PUMC. It became the Sichuan Provincial Key Laboratory of Human Blood Plasma Proteins in 2010. We have been focusing the research of blood plasma proteins since the establishment of the laboratory. 10 products derived from human blood plasma, including the first Chinese commercial human albumin, intramuscular immunoglobulin (IMIG), intravenous immunoglobulin (IVIG), Factor Ⅷ concentrate, prothrombin complex concentrate, α2-macroglobulin and transferrin, and a series of diagnostic kits for thrombosis and hemostasis have been developed. Several provincial and ministerial achievements have been obtained. We have accomplished projects under National High - Tech Research and Development Program of China (863 Program), Special Projects for National Public Health services, Science and Technology Development Programs of Sichuan, The R&D Infrastructure and Facility Development Program of Sichuan, Key Technology Research and Development Program of Sichuan, Science and Technology Development Programs of Sichuan Provincial Commission of Health and Family Planning, Science and Technology Development Programs of Chengdu and also industrial cooperative projects. Based on the principle of complementary advantages, win-win cooperation and common development, we established Joint Laboratory for Research on Efficacy of Blood Components with Institute of Materia Medica, CAMS/PUMC, Joint Laboratory for Biomedical Research with Institute of Basic Medical Sciences, CAMS/PUMC, Joint Laboratory for Diagnosis and Medical Biology with Institute of Medical Biology, CAMS/PUMC, Joint Laboratory for Comprehensive Utilization of Blood with China Biologic Products, Inc. and Joint Laboratory for In Vitro Diagnostics with Chengdu Union Biotechnology Co, LTD.. With 13 staffs, including 5 senior engineers and 12 masters and doctors, we have published more than 60 papers and obtained 20 approved patents.
Research Focus
We are interested in investigating the structure and function of blood plasma proteins and their therapeutic application in various diseases; evaluation of safety and efficacy of blood component products and their standardization of detection and preparation; development of blood plasma products and diagnostic kits for thrombosis and hemostasis.
PI簡介：
李長清
教授，研究生導(dǎo)師，從事輸血醫(yī)學(xué)及血液相關(guān)技術(shù)與產(chǎn)品研究24年。1995年年僅27歲即被中國醫(yī)學(xué)科學(xué)院破格晉升為副研究員，歷任中國醫(yī)學(xué)科學(xué)院輸血研究所蛋白室副主任、主任，血液制品部（技術(shù)開發(fā)部）副主任，生物技術(shù)中心主任，血液生化與分子生物學(xué)研究中心主任、四川省血漿蛋白質(zhì)重點實驗室主任；血液安全處處長等職?，F(xiàn)任國家血液安全督導(dǎo)檢查組專家、中國輸血雜志編委、中國輸血協(xié)會血液制品委員會委員、四川省輸血協(xié)會血液制品委員會副主任委員、四川醫(yī)學(xué)會委員、四川生化與分子生物學(xué)會理事等。主要從事血液相關(guān)蛋白與疾病及其療效機制、血漿蛋白結(jié)構(gòu)與功能相關(guān)性研究；血液成分制品安全性、有效性的評價體系建設(shè)及檢測關(guān)鍵技術(shù)與標(biāo)準(zhǔn)化研究；血液相關(guān)蛋白質(zhì)產(chǎn)品研究開發(fā)。曾先后參與人血白蛋白、免疫球蛋白、Ⅷ因子、PCC等多種血漿蛋白制品的研究開發(fā)，其中“利凡諾-低溫乙醇結(jié)合法分離血漿蛋白新工藝研究”獲四川省科技進(jìn)步一等獎；“中純Ⅷ因子制劑的研制”獲四川省科技進(jìn)步二等獎。近5年來又先后主持承擔(dān)四川省科技計劃支撐項目“血液制品生產(chǎn)廢棄組分再利用技術(shù)開發(fā)研究”、國家公益性衛(wèi)生行業(yè)科研重大專項 “輸血安全相關(guān)技術(shù)與標(biāo)準(zhǔn)研究”、“報廢血再利用技術(shù)應(yīng)用研究”以及國家科技重大專項“863”計劃項目“血液制品綜合純化新工藝研究及產(chǎn)品開發(fā)”、四川省科技計劃項目“血液制品深度開發(fā)關(guān)鍵技術(shù)及相關(guān)產(chǎn)品產(chǎn)業(yè)化開發(fā)”等項目。近年來，先后在國內(nèi)外科技核心期刊發(fā)表論文近50篇，國家發(fā)明專利20余項。
Tel：86-28-61648506 E-mail: lichangqing268@163.com
Changqing Li, professor at Inand supervisor for postgraduates, has been engaged in research of blood transfusion medicine and related technologies and products for 24 years. He worked as an associate professor at CAMS when he was only 27 in 1995. He served as deputy director and director of the department of protein, deputy director of the department of blood products, director of biotechnology center, director of blood biochemistry and molecular biology research center, director of Sichuan Provincial Key Laboratory of Human Blood Plasma Proteins, director of blood safety promotion department, etc. He is an expert in National Blood Safety Supervision Inspection Group, member of Editorial board of Chinese Journal of Blood Transfusion, member of blood products committee of CSBT, etc. His main research areas are the structure and function of plasma protein, establishment and standardization of the security and efficacy of blood products, R&D of blood products, etc.
Professor Li participated in the R&D of human albumin, IVIg, FVIII, PCC, etc. As one of the main participants, “rivanol-cold ethanol fractionation of plasma proteins” was awarded “the first prize of science and technology progress prize of Sichuan province” and “R&D of medium-purity coagulation factor Ⅷ” was awarded “the second prize of science and technology progress prize of Sichuan province”. In the last 5 years, he has been funded by Provincial Science and technology support program of Sichuan, special fund for Public Welfare Industry of Health and 863 program. In addition, he has published almost 50 papers and more than 20 patents.
林方昭
副主任技師。主要從事血栓與止血檢驗技術(shù)及產(chǎn)品的研發(fā)與產(chǎn)業(yè)化，血液相關(guān)蛋白成分與出凝血疾病的相關(guān)性研究，血液制品有效性、安全性評價及評價體系標(biāo)準(zhǔn)化研究，單克隆抗體制備技術(shù)研究以及對外檢測技術(shù)服務(wù)等。近年來承擔(dān)四川省科技支撐計劃項目“血栓與止血系列診斷試劑（盒）及配套儀器的研究開發(fā)”,四川省衛(wèi)生廳科學(xué)研究項目“系列凝血質(zhì)控物的研制與開發(fā)”，成都市科技局產(chǎn)學(xué)研聯(lián)合實驗室項目“血液病診斷聯(lián)合實驗室”和20余項橫向合作項目等，累計立項經(jīng)費350余萬元。作為項目負(fù)責(zé)人之一，完成了六種凝血診斷產(chǎn)品的研發(fā)及產(chǎn)品文號申報等工作，取得了6種凝血診斷產(chǎn)品生產(chǎn)文號。申請國家發(fā)明專利6項，在國內(nèi)外核心期刊發(fā)表論文20余篇。
Tel：86-28-61648541 E-mail: lfangzhao@126.com
Fangzhao Lin, born in 1966, is associate chief technician at IBT, CAMS/PUMC. She has been engaged in 1) research, development and industrialization of laboratory technology in thrombosis and hemostasis, 2) relationship between blood proteins and bleeding/thrombotic disorders, 3) efficacy, evaluation of safety and its standardization of blood products, 4) monoclonal antibody preparation and 5) laboratory testing services. Recent years, she has accomplished projects with funds of ~￥3.5 million supported by Key Technology Research and Development Program of Sichuan (Development of diagnostic kits and instruments for thrombosis and hemostasis), Science and Technology Development Programs of Sichuan Provincial Commission of Health and Family Planning (research and development of a series of coagulation factor controls) and Industry - Academy - Research Projects of Chengdu Science and Technology Bureau (Establishment of joint laboratory for diagnostic of hematologic diseases), and also 20 industrial cooperative projects. As one of the responsible persons, she got 6 official approvals for diagnosis of coagulation factors, 6 approved national invention patents and published about 20 papers.
